Sarcomatoid Carcinoma: Pleomorphic Carcinoma, Spindle Cell Carcinoma, Giant Cell Carcinoma, Carcinosarcoma, and Pulmonary Blastoma

  • Philip Hasleton


The 2004 World Health Organization (WHO) classification of lung tumors1 defines sarcomatoid carcinomas as a group of poorly differentiated, non-small-cell lung carcinomas that contain a component of sarcoma or sarcomalike (spindle or giant cell) differentiation. Five subgroups are currently recognized: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. These entities have been considered separately previously. The WHO does not recommend the use of the terms homologous or heterologous, as proposed by Wick et al.2 These tumors are rare, accounting for approximately between 0.3% and 1.3% of all lung malignancies.1


Giant Cell Sarcomatoid Carcinoma Pleomorphic Carcinoma Pulmonary Blastoma Giant Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004:51.Google Scholar
  2. 2.
    Wick MR, Ritter JH, Humphrey PA. Sarcomatoid carcinomas of the lung: a clinicopathologic review. Am J Clin Pathol 1997;108(1):40–53.PubMedGoogle Scholar
  3. 3.
    Travis W, et al. WHO international histological classification of tumours: histological typing of lung and pleural tumours. 3rd ed. New York: Springer Verlag, 1999.Google Scholar
  4. 4.
    Nappi O, et al. Biphasic and monophasic sarcomatoid carcinomas of the lung. A reappraisal of “carcinosarcomas” and “spindle-cell carcinomas.” Am J Clin Pathol 1994;102(3):331–340.PubMedGoogle Scholar
  5. 5.
    Nakatani Y, et al. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 2004;28(7):921–927.PubMedCrossRefGoogle Scholar
  6. 6.
    Sekine S, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol 2003;200(2):214–221.PubMedCrossRefGoogle Scholar
  7. 7.
    Wick MR, Ritter JH, Nappi O. Inflammatory sarcomatoid carcinoma of the lung: report of three cases and clinicopathologic comparison with inflammatory pseudotumors in adult patients. Hum Pathol 1995;26(9):1014–1021.PubMedCrossRefGoogle Scholar
  8. 8.
    Ro JY, et al. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992;69(2):376–386.PubMedCrossRefGoogle Scholar
  9. 9.
    Pelosi G, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003;27(9):1203–1215.PubMedCrossRefGoogle Scholar
  10. 10.
    Przygodzki RM, Koss MN, O’Leary TJ. Pleomorphic (giant and/or spindle cell) carcinoma of lung shows a high percentage of variant CYP1A12. Mol Diagn 2001;6(2):109–115.PubMedCrossRefGoogle Scholar
  11. 11.
    Holst VA, et al. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis. Am J Surg Pathol 1997;21(7):801–811.PubMedCrossRefGoogle Scholar
  12. 12.
    Fishback NF, et al. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994;73(12):2936–2945.PubMedCrossRefGoogle Scholar
  13. 13.
    Rossi G, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003;27(3):311–324.PubMedCrossRefGoogle Scholar
  14. 14.
    Humphrey PA, et al. Pulmonary carcinomas with a sarcomatoid element: an immunocytochemical and ultrastructural analysis. Hum Pathol 1988;19(2):155–165.PubMedCrossRefGoogle Scholar
  15. 15.
    Nakajima M, et al. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 1999;86(4):608–616.PubMedCrossRefGoogle Scholar
  16. 16.
    Suster S, Huszar M, Herczeg E. Spindle cell squamous carcinoma of the lung. Immunocytochemical and ultrastructural study of a case. Histopathology 1987;11(8):871–878.PubMedCrossRefGoogle Scholar
  17. 17.
    Matsui K, Kitagawa M, Miwa A. Lung carcinoma with spindle cell components: sixteen cases examined by immunohistochemistry. Hum Pathol 1992;23(11):1289–1297.PubMedCrossRefGoogle Scholar
  18. 18.
    Krefting I, et al. Pleomorphic carcinoma (spindle and giant cell) of the lung. Md Med J 1994;43:787–790.PubMedGoogle Scholar
  19. 19.
    Lucas DR, Pass HP, Lonardo F. Peripheral sarcomatoid (spindle cell/pleomorphic) carcinoma of lung; propensity for pleural and chest wall invasion and immunoprofile indistinguishable from sarcomatoid mesothelioma. Mod Pathol 2003;16:310A.Google Scholar
  20. 20.
    Banerjee SS, et al. Pseudoangiosarcomatous carcinoma: a clinicopathological study of seven cases. Histopathology 1992;21(1):13–23.PubMedGoogle Scholar
  21. 21.
    King JE. Clinicopathological studies of pleural mesothelioma. Southampton: (Personal Communication), 2004.Google Scholar
  22. 22.
    Lucas DR, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 2003;42(3):270–279.PubMedCrossRefGoogle Scholar
  23. 23.
    Przygodzki R, et al. Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis. Am J Clin Pathol 1996;106(4):487–492.PubMedGoogle Scholar
  24. 24.
    Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56(21):4965–4969.PubMedGoogle Scholar
  25. 25.
    Przygodzki RM, et al. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics 1998;8(6):503–511.PubMedCrossRefGoogle Scholar
  26. 26.
    Fischer D, et al. Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 1997;8(10):2055–2075.PubMedGoogle Scholar
  27. 27.
    Tao YS, et al. beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol 1996;134(5):1271–1281.PubMedCrossRefGoogle Scholar
  28. 28.
    Tilney LG, et al. Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each cross-link contribute? J Cell Biol 1998;143(1):121–133.PubMedCrossRefGoogle Scholar
  29. 29.
    Tseng Y, et al. Micromechanics and ultrastructure of actin filament networks crosslinked by human fascin: a comparison with alpha-actinin. J Mol Biol 2001;310(2):351–366.PubMedCrossRefGoogle Scholar
  30. 30.
    Yamashiro S, et al. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell 1998;9:993–1006.PubMedGoogle Scholar
  31. 31.
    Nash AD, Stout AP. Giant cell carcinoma of the lung; report of 5 cases. Cancer 1958;11(2):369–376.PubMedCrossRefGoogle Scholar
  32. 32.
    Hellstrom HR, Fisher ER. Giant cell carcinoma of lung. Cancer 1963;16:1080–1088.PubMedCrossRefGoogle Scholar
  33. 33.
    Flanagan P, Roeckel IE. Giant cell carcinoma of the lung. Anatomic and clinical correlation. Am J Med 1964;36:214–221.PubMedCrossRefGoogle Scholar
  34. 34.
    Guillan RA, Zelman S. Giant-cell carcinoma of the lung. Am J Clin Pathol 1966;46:427–432.PubMedGoogle Scholar
  35. 35.
    Lerner HJ. Giant cell carcinoma of the lung. Review of literature and report of five cases. Arch Surg 1967;94(6):891–894.PubMedGoogle Scholar
  36. 36.
    Dailey JE, Marcuse PM. Gonadotropin secreting giant cell carcinoma of the lung. Cancer 1969;24(2):388–396.PubMedCrossRefGoogle Scholar
  37. 37.
    Wellmann KF, Chafiian Y, Edelman E. Small bowel perforation from solitary metastasis of clinically undetected pulmonary giant cell carcinoma. Am J Gastroenterol 1969;51(2):145–150.PubMedGoogle Scholar
  38. 38.
    Razzuk MA, et al. Pulmonary giant cell carcinoma. Ann Thorac Surg 1976;21(6):540–545.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang NS, et al. Giant cell carcinoma of the lung. A light and electron microscopic study. Hum Pathol 1976;7(1):3–16.PubMedCrossRefGoogle Scholar
  40. 40.
    Takenaga A, et al. Giant cell carcinoma of the lung: comparative studies of the same cancer cells by light microscopy and scanning electron microscopy. Acta Cytol 1980;24(3):190–196.PubMedGoogle Scholar
  41. 41.
    Kodama T, et al. Large cell carcinoma of the lung—ultrastructural and immunohistochemical studies. Jpn J Clin Oncol 1985;15(2):431–441.PubMedGoogle Scholar
  42. 42.
    Shin MS, et al. Giant cell carcinoma of the lung. Clinical and roentgenographic manifestations. Chest 1986;89(3):366–369.PubMedCrossRefGoogle Scholar
  43. 43.
    Nakahashi H, et al. Undifferentiated carcinoma of the lung with osteoclast-like giant cells. Jpn J Surg 1987;17(3):199–203.PubMedCrossRefGoogle Scholar
  44. 44.
    Addis BJ, Dewar A, Thurlow NP. Giant cell carcinoma of the lung—immunohistochemical and ultrastructural evidence of dedifferentiation. J Pathol 1988;155(3):231–240.PubMedCrossRefGoogle Scholar
  45. 45.
    Horie A, et al. Clinicopathological study of pulmonary giant cell carcinomas with reference to prognosis of patients. J UOEH 1991;13(2):125–134.PubMedGoogle Scholar
  46. 46.
    Ginsberg SS, et al. Giant cell carcinoma of the lung. Cancer 1992;70(3):606–610.PubMedCrossRefGoogle Scholar
  47. 47.
    Attanoos RL, et al. Pulmonary giant cell carcinoma: pathological entity or morphological phenotype? Histopathology 1998;32(3):225–231.PubMedCrossRefGoogle Scholar
  48. 48.
    Prasad AR, et al. Primary giant cell tumors of the lung. Mod Pathol 2001;14:225A.Google Scholar
  49. 49.
    Yaturu S, et al. Gynecomastia attributable to human chorionic gonadotropin-secreting giant cell carcinoma of lung. Endocr Pract 2003;9(3):233–235.PubMedGoogle Scholar
  50. 50.
    Depue RH, Ballard BR. Pulmonary giant cell carcinoma: the relation to smoking. Br J Cancer 1989l;60(4):599–600.Google Scholar
  51. 51.
    Chemnitz J, Bichel P. Tumour cell-tumour cell emperipolesis studied by transmission electron microscopy. Exp Cell Res 1973;82(2):319–324.PubMedCrossRefGoogle Scholar
  52. 52.
    Humble JG, Jayne WH, Pulvertaft RJ. Biological interaction between lymphocytes and other cells. Br J Haematol 1956;2(3):283–294.PubMedCrossRefGoogle Scholar
  53. 53.
    Iizuka M, et al. Joining of the c-myc gene and a line 1 family member on chromosome 8 in a human primary giant cell carcinoma of the lung. Cancer Res 1990;50(11):3345–3350.PubMedGoogle Scholar
  54. 54.
    Ishida T, et al. Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg 1990;100(6):844–852.PubMedGoogle Scholar
  55. 55.
    Cabarcos A, Gomez Dorronsoro M, Lobo Beristain JL. Pulmonary carcinosarcoma: a case study and review of the literature. Br J Dis Chest 1985;79(1):83–94.PubMedCrossRefGoogle Scholar
  56. 56.
    Koss MN, Hochholzer L, Frommelt RA. Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol 1999;23(12):1514–1526.PubMedCrossRefGoogle Scholar
  57. 57.
    Reynolds S, et al. Carcinosarcoma of the lung: an unusual cause of empyema. Respir Med 1995;89(1):73–75.PubMedCrossRefGoogle Scholar
  58. 58.
    Farrell DJ, Cooper PN, Malcolm AJ, Carcinosarcoma of lung associated with asbestosis. Histopathology 1995;27(5):484–486.PubMedCrossRefGoogle Scholar
  59. 59.
    Pankowski J, et al. Carcinosarcoma of the lung. Report of three cases. J Cardiovasc Surg (Torino) 1998;39(1):121–125.Google Scholar
  60. 60.
    Dacic S, et al. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol 2002;26(4):510–516.PubMedCrossRefGoogle Scholar
  61. 61.
    Eng J, Sabanathan S. Carcinosarcoma of the lung with gastrointestinal metastasis. Case report. Scand J Thorac Cardiovasc Surg 1992;26(2):161–162.PubMedGoogle Scholar
  62. 62.
    Rainosek DE, et al. Sarcomatoid carcinoma of the lung. A case with atypical carcinoid and rhabdomyosarcomatous components. Am J Clin Pathol 1994;102(3):360–364.PubMedGoogle Scholar
  63. 63.
    Heckman CJ, et al. Pulmonary blastoma with rhabdomyosarcomatous differentiation: an electron microscopic and immunohistochemical study. Am J Surg Pathol 1988;12(1):35–40.PubMedCrossRefGoogle Scholar
  64. 64.
    Peacock MJ, Whitwell F. Pulmonary blastoma. Thorax 1976;31(2):197–204.PubMedCrossRefGoogle Scholar
  65. 65.
    Jacobsen M, Francis D. Pulmonary blastoma. A clinicopathological study of eleven cases. Acta Pathol Microbiol Scand [A] 1980;88(3):151–160.Google Scholar
  66. 66.
    Medbery CA 3rd, et al. Pulmonary blastoma. Case report and literature review of chemotherapy experience. Cancer 1984;53(11):2413–2416.PubMedCrossRefGoogle Scholar
  67. 67.
    Marcus PB, Dieb TM, Martin JH. Pulmonary blastoma: an ultrastructural study emphasizing intestinal differentiation in lung tumors. Cancer 1982;49(9):1829–1833.PubMedCrossRefGoogle Scholar
  68. 68.
    Korbi S, et al. Pulmonary blastoma. Immunohistochemical and ultrastructural studies of a case. Histopathology 1987;11(7):753–760.PubMedCrossRefGoogle Scholar
  69. 69.
    Addis BJ, Corrin B. Pulmonary blastoma, carcinosarcoma and spindle-cell carcinoma: an immunohistochemical study of keratin intermediate filaments. J Pathol 1985;147(4):291–301.PubMedCrossRefGoogle Scholar
  70. 70.
    Berean K, et al. Immunohistochemical characterization of pulmonary blastoma. Am J Clin Pathol 1988;89(6):773–777.PubMedGoogle Scholar
  71. 71.
    Weisbrod GL, Chamberlain DW, Tao LC. Pulmonary blastoma, report of three cases and a review of the literature. J Can Assoc Radiol 1988;39:130–136.Google Scholar
  72. 72.
    Cohen RE, et al. Pulmonary blastoma with malignant melanoma component. Arch Pathol Lab Med 1990;114(10):1076–1078.PubMedGoogle Scholar
  73. 73.
    Cosgrove MM, Chandrasoma PT, Martin SE. Diagnosis of pulmonary blastoma by fine-needle aspiration biopsy: cytologic and immunocytochemical findings. Diagn Cytopathol 1991;7(1):83–87.PubMedCrossRefGoogle Scholar
  74. 74.
    Yousem SA, et al. Pulmonary blastoma. An immunohistochemical analysis with comparison with fetal lung in its pseudoglandular stage. Am J Clin Pathol 1990;93(2):167–175.PubMedGoogle Scholar
  75. 75.
    Koss MN, Hochholzer L, O’Leary T. Pulmonary blastomas. Cancer 1991;67(9):2368–2381.PubMedCrossRefGoogle Scholar
  76. 76.
    Siegel RJ, et al. Pulmonary blastoma with germ cell (yolk sac) differentiation: report of two cases. Mod Pathol 1991;4(5):566–570.PubMedGoogle Scholar
  77. 77.
    McCann MP, Fu YS, Kay S. Pulmonary blastoma: A light and electron microscopic study. Cancer 1976;38(2):789–797.PubMedCrossRefGoogle Scholar
  78. 78.
    Inoue H, et al. Pulmonary blastoma. Comparison between its epithelial components and fetal bronchial epithelium. Acta Pathol Jpn 1992;42(12):884–892.PubMedGoogle Scholar
  79. 79.
    Vassilopoulos PP, et al. Pulmonary blastoma presenting with massive hemothorax. Chest 1992;102(2):649–650.PubMedCrossRefGoogle Scholar
  80. 80.
    Miller RR, Champagne K, Murray RC. Primary pulmonary germ cell tumor with blastomatous differentiation. Chest 1994;106(5):1595–1596.PubMedCrossRefGoogle Scholar
  81. 81.
    Yang P, et al. Pulmonary blastoma: an ultrastructural and immunohistochemical study with special reference to nuclear filament aggregation. Ultrastruct Pathol 1995;19(6):501–509.PubMedCrossRefGoogle Scholar
  82. 82.
    Novotny JE, Huiras CM. Resection and adjuvant chemotherapy of pulmonary blastoma: a case report. Cancer 1995;76(9):1537–1539.PubMedCrossRefGoogle Scholar
  83. 83.
    Pacinda SJ, et al. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Hum Pathol 1996;27(6):542–546.PubMedCrossRefGoogle Scholar
  84. 84.
    LeMense GP, Reed CE, Silvestri GA. Pulmonary blastoma: a rare lung malignancy. Lung Cancer 1996;15(2):233–237.PubMedCrossRefGoogle Scholar
  85. 85.
    Theegarten D, Zorn M, Philippou S. Proliferative activity, p53 accumulation and neoangiogenesis in pulmonary carcinosarcomas and pulmonary blastomas. Gen Diagn Pathol 1998;143(5–6):265–270.PubMedGoogle Scholar
  86. 86.
    Cutler CS, et al. Pulmonary blastoma: case report of a patient with a 7-year remission and review of chemotherapy experience in the world literature. Cancer 1998;82(3):462–467.PubMedCrossRefGoogle Scholar
  87. 87.
    Robert J, et al. Pulmonary blastoma: report of five cases and identification of clinical features suggestive of the disease. Eur J Cardiothorac Surg 2002;22(5):708–711.PubMedCrossRefGoogle Scholar
  88. 88.
    Bodner SM, Koss MN. Mutations in the p53 gene in pulmonary blastomas: immunohistochemical and molecular studies. Hum Pathol 1996;27(11):1117–1123.PubMedCrossRefGoogle Scholar
  89. 89.
    Ramos SG, Rezende GG, Faccio AA. A rare presentation of biphasic pulmonary blastoma. Arch Pathol Lab Med 2002;126(7):875–876.PubMedGoogle Scholar
  90. 90.
    Garcia-Escudero A, et al. Thyroid transcription factor-1 expression in pulmonary blastoma. Histopathology 2004;44(5):507–508.PubMedCrossRefGoogle Scholar
  91. 91.
    Barson AJ, Jones AW, Lodge KV. Pulmonary blastoma. J Clin Pathol 1968;21(4):480–485.PubMedCrossRefGoogle Scholar
  92. 92.
    Olenick SJ, Fan CC, Ryoo JW. Mixed pulmonary blastoma and carcinosarcoma. Histopathology 1994;25(2):171–174.PubMedCrossRefGoogle Scholar
  93. 93.
    Roth JA, Elguezabal A. Pulmonary blastoma evolving into carcinosarcoma. A case study. Am J Surg Pathol 1978;2(4):407–413.PubMedCrossRefGoogle Scholar
  94. 94.
    Tanaka Y, et al. Pancreatoblastoma: optically clear nuclei in squamoid corpuscles are rich in biotin. Mod Pathol 1998;11(10):945–949.PubMedGoogle Scholar
  95. 95.
    Abraham SC, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001;159(5):1619–1627.PubMedGoogle Scholar
  96. 96.
    Tsujimoto M, Noguchi M, Taki I. Immunohistochemical and electron microscopic study of the intranuclear inclusion bodies containing biotin in the ovarian endometrioid carcinoma. J Clin Electron Microsc 1991;24:783–784.Google Scholar
  97. 97.
    Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001;194(1):59–67.PubMedCrossRefGoogle Scholar
  98. 98.
    Shigemitsu K, et al. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001;20(31):4249–4257.PubMedCrossRefGoogle Scholar
  99. 99.
    Ueda M, et al. Mutations of the beta-and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 2001;85(1):64–68.PubMedCrossRefGoogle Scholar
  100. 100.
    Hommura F, et al. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer 2002;94(3):752–758.PubMedCrossRefGoogle Scholar
  101. 101.
    Behrens J. Control of beta-catenin signaling in tumor development. Ann N Y Acad Sci 2000;910:21–33; discussion 33–35.PubMedCrossRefGoogle Scholar
  102. 102.
    Momand J, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69(7):1237–1245.PubMedCrossRefGoogle Scholar
  103. 103.
    Holst V, et al. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis. Am J Surg Pathol 1997;21(7):801–811.PubMedCrossRefGoogle Scholar
  104. 104.
    Mountain CF. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest 1995;108(1):246–254.PubMedCrossRefGoogle Scholar
  105. 105.
    Rodenhuis S, et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317(15):929–935.PubMedCrossRefGoogle Scholar
  106. 106.
    Rosell R, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8(9):2407–2412.PubMedGoogle Scholar
  107. 107.
    vonRohr A, et al. Point mutations in codon 12 of the K-ras oncogene: incidence and clinical significance in patients with non-small cell lung cancer (meeting abstract). Ann Oncol 1992;3(suppl 5):9.Google Scholar
  108. 108.
    Makela V, Mattila S, Makinen J. Plasma cell granuloma (histiocytoma) of the lung and pleura. Report on three cases. Acta Pathol Microbiol Scand [A] 1972;80(5):634–640.Google Scholar
  109. 109.
    Muraoka S, et al. Plasma cell granuloma of the lung with extrapulmonal extension. Immunohistochemical and electron microscopic studies. Acta Pathol Jpn 1985;35(4):933–944.PubMedGoogle Scholar
  110. 110.
    Hutchins GM, Eggleston JC. Unusual presentation of pulmonary inflammatory pseudotumor (plasma cell granuloma) as esophageal obstruction. Am J Gastroenterol 1979;71(5):501–504.PubMedGoogle Scholar
  111. 111.
    Kim I, et al. Inflammatory pseudotumor of the lung manifesting as a posterior mediastinal mass. Pediatr Radiol 1992;22(6):467–468.PubMedCrossRefGoogle Scholar
  112. 112.
    Hong HY, Castelli MJ, Walloch JL. Pulmonary plasma cell granuloma (inflammatory pseudotumor) with invasion of thoracic vertebra. Mt Sinai J Med 1990;57(2):117–121.PubMedGoogle Scholar
  113. 113.
    Coffin CM, et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995;19(8):859–872.PubMedCrossRefGoogle Scholar
  114. 114.
    Hussong JW, et al. Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Mod Pathol 1999;12(3):279–286.PubMedGoogle Scholar
  115. 115.
    Coffin CM, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14(6):569–576.PubMedCrossRefGoogle Scholar
  116. 116.
    Flieder DB, Suster S, Moran CA. Idiopathic fibroinflammatory (fibrosing/sclerosing) lesions of the mediastinum: a study of 30 cases with emphasis on morphologic heterogeneity. Mod Pathol 1999;12(3):257–264.PubMedGoogle Scholar
  117. 117.
    Litzky LA, Brooks JJ. Cytokeratin immunoreactivity in malignant fibrous histiocytoma and spindle cell tumors: comparison between frozen and paraffin-embedded tissues. Mod Pathol 1992;5(1):30–34.PubMedGoogle Scholar
  118. 118.
    Yousem SA, Hochholzer L. Malignant fibrous histiocytoma of the lung. Cancer 1987;60(10):2532–2541.PubMedCrossRefGoogle Scholar
  119. 119.
    Fukayama M, et al. Pulmonary and pleural thymoma. Diagnostic application of lymphocyte markers to the thymoma of unusual site. Am J Clin Pathol 1988;89(5):617–621.PubMedGoogle Scholar
  120. 120.
    Hishima T, et al. CD70 expression in thymic carcinoma. Am J Surg Pathol 2000;24(5):742–746.PubMedCrossRefGoogle Scholar
  121. 121.
    Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991;67(4):1025–1032.PubMedCrossRefGoogle Scholar
  122. 122.
    Kuo TT, Chan JK. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile. Am J Surg Pathol 1998;22(12):1474–1481.PubMedCrossRefGoogle Scholar
  123. 123.
    Suster S, Moran CA. Spindle cell thymic carcinoma: clinicopathologic and immunohistochemical study of a distinctive variant of primary thymic epithelial neoplasm. Am J Surg Pathol 1999;23(6):691–700.PubMedCrossRefGoogle Scholar
  124. 124.
    Attanoos RL, et al. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology 2002;41(1):42–49.PubMedCrossRefGoogle Scholar
  125. 125.
    Attanoos RL, Thomas DH, Gibbs AR. Synchronous diffuse malignant mesothelioma and carcinomas in asbestosexposed individuals. Histopathology 2003;43(4):387–392.PubMedCrossRefGoogle Scholar
  126. 126.
    Cavazza A, et al. Cytokeratin-positive malignant solitary fibrous tumour of the pleura: an unusual pitfall in the diagnosis of pleural spindle cell neoplasms. Histopathology 2003;43(6):606–608.PubMedCrossRefGoogle Scholar
  127. 127.
    Dei Tos A, et al. Immunohistochemical demonstration of glycoprotein p30/32 mic2 (CD99) in synovial sarcoma: a potential cause of diagnostic confusion. Appl Immunohistochem 1995;3:168–173.Google Scholar
  128. 128.
    Suster S, Fisher C, Moran C. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22:863–872.PubMedCrossRefGoogle Scholar
  129. 129.
    Renshaw A. O-13 (CD99) in spindle-cell tumors—reactivity with hemangiopericytoma, solitary fibrous tumor, synovial sarcoma, and meningioma but rarely with sarcomatoid mesothelioma. Appl Immunohistochem 1995;3:250–256.Google Scholar
  130. 130.
    Cavazza A, et al. Lung tumors with a rhabdoid phenotype. Am J Clin Pathol 1996;105(2):182–188.PubMedGoogle Scholar
  131. 131.
    Dueland S, et al. Treatment and outcome of patients with extragonadal germ cell tumours—the Norwegian Radium Hospital’s experience 1979–1994. Br J Cancer 1998;77(2):329–335.PubMedGoogle Scholar
  132. 132.
    Guarino M, et al. Sarcomatoid carcinomas: pathological and histopathogenetic considerations. Pathology 1996;28(4):298–305.PubMedCrossRefGoogle Scholar
  133. 133.
    Hasleton PS, et al. Pleural myxoma associated with a pulmonary squamous cell carcinoma. Respir Med 1989;83(5):443–444.PubMedCrossRefGoogle Scholar
  134. 134.
    McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55(5):321–325.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Philip Hasleton
    • 1
  1. 1.Department of Histopathology, Clinical Sciences BlockManchester Royal InfirmaryManchesterUK

Personalised recommendations